Latanoprost Olikla (Latanoprost)

Latanoprost mimics prostaglandin F2α and activates FP receptors in the ciliary body. This activation increases uveoscleral outflow of aqueous humor, the fluid that fills the front part of the eye, thereby decreasing intra‑ocular pressure and protecting the optic nerve.

The dosing regimen for Latanoprost Olikla is determined by the prescribing ophthalmologist. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and timing should follow the prescriber’s instructions.

Safety data for latanoprost in pregnancy and lactation are limited. The product should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latanoprost is a prostaglandin analog, a class known for once‑daily dosing and strong IOP‑lowering efficacy. Compared with beta‑blocker or carbonic anhydrase inhibitor drops, latanoprost often provides greater pressure reduction with a convenient dosing schedule, though individual response may vary.

Latanoprost Olikla should be stored at room temperature, below 25 °C, in its original container. Protect the bottle from light and moisture, and keep it out of reach of children. Do not freeze the solution.

The product is an ophthalmic solution applied as a single drop into the conjunctival sac of the prescribed eye(s) once daily, usually in the evening. Patients should wash their hands, avoid touching the tip of the bottle to the eye or any surface, and close the eye gently after instillation.

Serious but rare risks include severe allergic reactions, corneal edema, uveitis, and sudden vision loss. Patients should seek immediate medical attention if they experience intense eye pain, swelling, redness that worsens, or any sudden change in vision.

Latanoprost Olikla is contraindicated in patients with active ocular infections, inflammation, or hypersensitivity to latanoprost or any component of the formulation. It should also be used with caution in individuals with a history of uveitis or ocular surgery until cleared by an eye specialist.